NASDAQ:AKCAAkcea Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Akcea Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $14.87 -0.88 (-5.59 %) (As of 04/8/2020 03:32 AM ET) Add Compare Share Today's Range$14.77Now: $14.87▼$16.4750-Day Range$11.15MA: $15.02▼$18.4552-Week Range$8.00Now: $14.87▼$32.35Volume269,700 shsAverage Volume274,200 shsMarket Capitalization$1.50 billionP/E Ratio32.33Dividend YieldN/ABeta1.33 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Akcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. operates as a subsidiary of Ionis Pharmaceuticals, Inc.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingAkcea Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $34.67, Akcea Therapeutics has a potential upside of 133.1% from its current price of $14.87.Amount of Analyst CoverageAkcea Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesAkcea Therapeutics has received 333 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAkcea Therapeutics has received 346 “underperform” votes. (Add your “underperform” vote.)Community SentimentAkcea Therapeutics has received 50.96% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Akcea Therapeutics and other stocks. Vote “Outperform” if you believe AKCA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AKCA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAkcea Therapeutics does not currently pay a dividend.Dividend GrowthAkcea Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Akcea Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $123,743.00 in company stock.Percentage Held by InsidersOnly 1.50% of the stock of Akcea Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 20.65% of the stock of Akcea Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Akcea Therapeutics are expected to grow by 18.36% in the coming year, from ($2.07) to ($2.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Akcea Therapeutics is 32.33, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 11.99.Price to Earnings Ratio vs. SectorThe P/E ratio of Akcea Therapeutics is 32.33, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 20.41.Price to Book Value per Share RatioAkcea Therapeutics has a P/B Ratio of 2.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.30 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AKCA Previous Symbol CUSIPN/A CIK1662524 Webhttp://www.akceatx.com/ Phone617-207-0202Debt Debt-to-Equity Ratio0.03 Current Ratio11.83 Quick Ratio11.62Price-To-Earnings Trailing P/E Ratio32.33 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$488.54 million Price / Sales3.08 Cash Flow$0.52 per share Price / Cash Flow28.51 Book Value$5.78 per share Price / Book2.57Profitability EPS (Most Recent Fiscal Year)$0.48 Net Income$40.77 million Net Margins8.35% Return on Equity10.03% Return on Assets8.70%Miscellaneous Employees248 Outstanding Shares101,074,000Market Cap$1.50 billion Next Earnings Date5/13/2020 (Estimated) OptionableOptionable Receive AKCA News and Ratings via Email Sign-up to receive the latest news and ratings for AKCA and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:AKCA Rates by TradingView Akcea Therapeutics (NASDAQ:AKCA) Frequently Asked Questions How has Akcea Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Akcea Therapeutics' stock was trading at $13.44 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AKCA shares have increased by 10.6% and is now trading at $14.87. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Akcea Therapeutics? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akcea Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Akcea Therapeutics. When is Akcea Therapeutics' next earnings date? Akcea Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for Akcea Therapeutics. How were Akcea Therapeutics' earnings last quarter? Akcea Therapeutics Inc (NASDAQ:AKCA) issued its earnings results on Tuesday, February, 25th. The company reported $0.86 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $2.10 by $1.24. The firm earned $277.48 million during the quarter, compared to analysts' expectations of $225.94 million. Akcea Therapeutics had a net margin of 8.35% and a return on equity of 10.03%. The company's quarterly revenue was up 2620.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.79) EPS. View Akcea Therapeutics' earnings history. What price target have analysts set for AKCA? 4 analysts have issued 1 year target prices for Akcea Therapeutics' stock. Their forecasts range from $24.00 to $41.00. On average, they expect Akcea Therapeutics' share price to reach $34.67 in the next twelve months. This suggests a possible upside of 133.1% from the stock's current price. View analysts' price targets for Akcea Therapeutics. Has Akcea Therapeutics been receiving favorable news coverage? Headlines about AKCA stock have trended very negative recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Akcea Therapeutics earned a news impact score of -3.3 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutAkcea Therapeutics. Are investors shorting Akcea Therapeutics? Akcea Therapeutics saw a drop in short interest during the month of March. As of March 13th, there was short interest totaling 3,366,000 shares, a drop of 7.0% from the February 27th total of 3,620,000 shares. Based on an average daily volume of 254,300 shares, the short-interest ratio is presently 13.2 days. Currently, 36.4% of the shares of the company are short sold. View Akcea Therapeutics' Current Options Chain. Who are some of Akcea Therapeutics' key competitors? Some companies that are related to Akcea Therapeutics include Jazz Pharmaceuticals (JAZZ), Ascendis Pharma A/S (ASND), Bausch Health Companies (BHC), Reata Pharmaceuticals (RETA), Forty Seven (FTSV), United Therapeutics (UTHR), Global Blood Therapeutics (GBT), Evotec (EVTCY), Nektar Therapeutics (NKTR), Blueprint Medicines (BPMC), Mirati Therapeutics (MRTX), Emergent Biosolutions (EBS), FibroGen (FGEN), Zai Lab (ZLAB) and Ultragenyx Pharmaceutical (RARE). What other stocks do shareholders of Akcea Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Akcea Therapeutics investors own include Ionis Pharmaceuticals (IONS), Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Achaogen (AKAO), Ciena (CIEN), AMC Entertainment (AMC), Apollo Global Management (APO), Associated British Foods (ABF) and Chaarat Gold (CGH). Who are Akcea Therapeutics' key executives? Akcea Therapeutics' management team includes the following people: Ms. Paula Soteropoulos, CEO & Director (Age 51)Mr. Michael F. MacLean, Chief Financial Officer (Age 53)Dr. Louis St. Laurence O'Dea FRCPC, MB, BCh, BAO, FRCP(C), Chief Medical Officer (Age 68)Ms. Sarah Boyce, Pres & Director (Age 47)Mr. Jeffrey M. Goldberg, Chief Operating Officer (Age 46) When did Akcea Therapeutics IPO? (AKCA) raised $125 million in an IPO on Friday, July 14th 2017. The company issued 9,600,000 shares at a price of $12.00-$14.00 per share. Cowen and Company, Stifel and Wells Fargo Securities served as the underwriters for the IPO and BMO Capital Markets was co-manager. What is Akcea Therapeutics' stock symbol? Akcea Therapeutics trades on the NASDAQ under the ticker symbol "AKCA." How do I buy shares of Akcea Therapeutics? Shares of AKCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Akcea Therapeutics' stock price today? One share of AKCA stock can currently be purchased for approximately $14.87. How big of a company is Akcea Therapeutics? Akcea Therapeutics has a market capitalization of $1.50 billion and generates $488.54 million in revenue each year. The company earns $40.77 million in net income (profit) each year or $0.48 on an earnings per share basis. Akcea Therapeutics employs 248 workers across the globe. View additional information about Akcea Therapeutics. What is Akcea Therapeutics' official website? The official website for Akcea Therapeutics is http://www.akceatx.com/. How can I contact Akcea Therapeutics? Akcea Therapeutics' mailing address is 22 BOSTON WHARF RD 9TH FLOOR, BOSTON MA, 02210. The company can be reached via phone at 617-207-0202 or via email at [email protected] This page was last updated on 4/8/2020 by MarketBeat.com StaffFeatured Article: Most Volatile Stocks – What Investors Need to Know to Maximize ROI
